<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005804</url>
  </required_header>
  <id_info>
    <org_study_id>1467.00</org_study_id>
    <secondary_id>FHCRC-1467.00</secondary_id>
    <secondary_id>NCI-H00-0054</secondary_id>
    <secondary_id>CDR0000067780</secondary_id>
    <nct_id>NCT00005804</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in&#xD;
      chemotherapy use different ways to stop cancer cells from dividing so they stop growing or&#xD;
      die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give&#xD;
      higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating&#xD;
      patients who have hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the incidence of graft-versus-host disease (GVHD) grades III and IV in patients&#xD;
           with hematologic malignancies treated with bone marrow transplantation (BMT) using&#xD;
           donors with 1 HLA-A or B non-cross-reactive group mismatch vs control patients&#xD;
           previously treated with BMT using donors with 1 HLA-A or B cross-reactive group (CREG)&#xD;
           mismatch.&#xD;
&#xD;
        -  Compare the incidence of GVHD grades III and IV in patients with hematologic&#xD;
           malignancies treated with BMT using donors with 1 HLA-A or B CREG mismatch vs control&#xD;
           patients previously treated with BMT using matched donors.&#xD;
&#xD;
        -  Determine the relevance of HLA-DRB1 or DQB1 allele mismatching in BMT using donors&#xD;
           matched for HLA-A, B, and C.&#xD;
&#xD;
      OUTLINE: Beginning at least 3 weeks after completion of cytoreductive combination&#xD;
      chemotherapy, patients under age 18 undergo total body irradiation (TBI) twice a day on days&#xD;
      -7 to -4. Patients age 18 and over undergo TBI twice a day on days -6 to -4. All patients&#xD;
      then receive cyclophosphamide IV daily on days -3 and -2. Males with acute lymphocytic&#xD;
      leukemia, high-grade lymphoma, intermediate-grade lymphoma, or marrow or CNS involvement&#xD;
      receive radiotherapy boost to the testes. On day 0, patients receive infusion of bone marrow&#xD;
      from unrelated donors with 1 of the following: 1 HLA-A or B non-cross-reactive group&#xD;
      mismatch; 1 HLA-A or B cross-reactive group mismatch; or an HLA-A, B, and C match with an&#xD;
      HLA-DRB1 or DQB1 mismatch.&#xD;
&#xD;
      Patients are followed every 6 months for 2 years and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous/Nonmalignant Condition</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven hematologic malignancy of 1 of the following types:&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) in chronic, accelerated, or blast* phase&#xD;
&#xD;
               -  Acute leukemia with high-risk features at diagnosis such as:&#xD;
&#xD;
                    -  Philadelphia chromosome-positive acute lymphocytic leukemia**&#xD;
&#xD;
                    -  Acute myeloid leukemia with high-risk cytogenetics such as inv (3), t(3;3)&#xD;
                       del(5q), -5, del(7q), -7, +8, +11, abnormal 12p, del(20q), -20, or complex&#xD;
                       abnormalities**&#xD;
&#xD;
               -  Acute leukemia with failure after one course of induction chemotherapy&#xD;
&#xD;
               -  Acute leukemia in first relapse* or second remission&#xD;
&#xD;
               -  High-risk lymphoblastic lymphoma in first remission&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma, Hodgkin's disease, or other malignant lymphoproliferative&#xD;
                  disease after first remission, if an autologous transplantation is not indicated&#xD;
&#xD;
               -  Myelodysplastic or myeloproliferative syndromes ineligible for Protocol FHCRC-179&#xD;
                  NOTE: * For patients with acute leukemia in relapse or CML in blast crisis, the&#xD;
                  search for an unrelated donor begins only if: High probability that the patient's&#xD;
                  medical condition will remain stable for the 3 to 6-month period needed to find a&#xD;
                  donorAn attempt at remission induction has been undertaken Referring physician&#xD;
                  and patient accept possibility that search for donor will be canceled if&#xD;
                  patient's condition worsens&#xD;
&#xD;
        NOTE: ** For newly diagnosed patients with high-risk acute leukemia, early referral is&#xD;
        encouraged so that an unrelated donor search may begin immediately&#xD;
&#xD;
          -  Availability of an unrelated donor with:&#xD;
&#xD;
               -  1 HLA-A or B non-cross-reactive group (non-CREG) mismatch (except in CML in&#xD;
                  chronic phase or myelodysplastic syndrome) OR&#xD;
&#xD;
               -  1 HLA-A or B CREG mismatch OR&#xD;
&#xD;
               -  An HLA-A, B, and C match with an HLA-DRB1 or DQB1 mismatch (no double mismatch)&#xD;
                  if 1 of the above 2 donor types unavailable&#xD;
&#xD;
                    -  No more than 1 HLA-A, B, and C mismatch&#xD;
&#xD;
          -  No availability of an HLA-identical sibling or haploidentical relative incompatible&#xD;
             for 0 or 1 HLA-A or B locus of the nonshared haplotypes&#xD;
&#xD;
               -  For patients with diagnosis other than CML in chronic phase, 1 HLA-DR&#xD;
                  locus-incompatible related donor has priority over an HLA compatible or class IA&#xD;
                  or B CREG locus antigen-incompatible unrelated donor&#xD;
&#xD;
          -  No severe aplastic anemia&#xD;
&#xD;
          -  No leukoencephalopathy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 51&#xD;
&#xD;
          -  Eligible for transplantation until age 52 if the donor is identified prior to&#xD;
             patient's 51st birthday&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No severe hepatic disease, including acute hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2 times normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac insufficiency requiring treatment&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe hypoxemia (i.e., PO2 less than 70 mm Hg) with decreased DLCO (i.e., DLCO&#xD;
             less than 70% predicted) OR&#xD;
&#xD;
          -  No mild hypoxemia (i.e., PO2 less than 80 mm Hg) with severely decreased DLCO (i.e.,&#xD;
             DLCO less than 60% predicted)&#xD;
&#xD;
          -  No pulmonary fibrosis&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other nonmalignant disease that would severely limit life expectancy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No contraindication to total body irradiation (TBI)&#xD;
&#xD;
          -  Patients excluded from this study because of contraindication to TBI may be treated on&#xD;
             protocol FHCRC-739&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy greater than 3,000 cGy to whole brain&#xD;
&#xD;
          -  At least 6 months since prior involved-field radiotherapy greater than 1,500 cGy to&#xD;
             chest or abdomen&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Anasetti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>August 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2003</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

